Recent Finacing
Recent Raise
Neurona Therapeutics develops allogeneic, off-the-shelf neural cell therapies — including NRTX-1001 (GABAergic interneurons) — as single-dose, targeted implants to repair dysfunctional neural circuits, advancing Phase 1/2 trials for focal epilepsy.
